NTAH update

Deltex Medical Group PLC
28 March 2008

                            Deltex Medical Group plc

                First NHS National Technology Adoption Hub sales

28 March 2008 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the UK's leading haemodynamic monitoring company, announced in October 2007 that
its CardioQ(TM) system was one of the first products to be selected under the 
NHS National Technology Adoption Hub (NTAH) programme. The Company today 
announces that it has now made its first sale in connection with the NTAH.

The NTAH has been established as a key element of the NHS innovation agenda
which is aimed at ensuring that NHS patients in England benefit earlier from
proven new medical technologies. The NTAH website is
www.technologyadoptionhub.nhs.uk.

The Whittington Hospital in London is one of three hospitals participating in
the first phase of the NTAH project. It has purchased four CardioQ monitors for
use in its operating theatres, which are in addition to the five that it already
owns, which are primarily deployed in Intensive Care. The Company expects the
hospital to soon increase its regular probe ordering level as it implements its
plans to expand its use of CardioQ.

Deltex Medical's Chief Executive, Andy Hill commented:

'This order means that the Whittington Hospital now owns sufficient monitors to
move forward with implementing the CardioQ across all those groups of patients
where benefit has already been proven.'

For further information, please contact:-

Deltex Medical Group plc                 01243 774 837
Nigel Keen, Chairman                     [e-mail]
Andy Hill, Chief Executive               [e-mail]
Ewan Phillips, Finance Director          [e-mail]

Gavin Anderson & Company                 0207 554 1400
Deborah Walter                           [e-mail]
Robert Speed                             [e-mail]

Charles Stanley Securities               020 7149 6000
Philip Davies                            [e-mail]
Russell Cook                             [e-mail]

Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM) monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already around 1,500 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
  ND
NRAEAPDXALLPEFE